A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Public ClinicalTrials.gov record NCT01691898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This multicenter, open-label study will evaluate the safety and efficacy of pinatuzumab vedotin (DCDT2980S) or polatuzumab vedotin (DCDS4501A) in combination with rituximab (RTX), as well as of polatuzumab vedotin in combination with obinutuzumab in participants with relapsed or refractory (r/r) follicular lymphoma (FL) and r/r diffuse large B-cell lymphoma (DLBCL).
Study identification
- NCT ID
- NCT01691898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 231 participants
Conditions and interventions
Conditions
Interventions
- Obinutuzumab Drug
- Pinatuzumab Vedotin Drug
- Polatuzumab Vedotin Drug
- Rituximab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 27, 2012 (Actual)
- Primary completion
- Mar 8, 2017 (Actual)
- Completion
- Feb 7, 2019 (Actual)
- Last update posted
- Feb 21, 2020
2012 – 2019
United States locations
- U.S. sites
- 26
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Stanford Cancer Center | Stanford | California | 94305-5820 | — |
| Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center | Denver | Colorado | 80218 | — |
| Georgetown University Medical Center Lombardi Cancer Center | Washington D.C. | District of Columbia | 20007 | — |
| Florida Cancer Specialists - Fort Myers (Colonial Center Dr) | Fort Myers | Florida | 33905 | — |
| Florida Cancer Specialists; Sarasota | Sarasota | Florida | 34232 | — |
| Univ of Michigan Med School; Hematology Oncology | Ann Arbor | Michigan | 48109 | — |
| Comprehensive Cancer Centers of Nevada - Eastern Avenue | Las Vegas | Nevada | 89169 | — |
| Hematology Oncology Associates; Carol G. Simon Ctr | Morristown | New Jersey | 07960 | — |
| Regional Cancer Care Associates LLC - Morristown | Morristown | New Jersey | 07962 | — |
| Roswell Park Cancer Inst. | Buffalo | New York | 14263 | — |
| New York University Cancer Cen | New York | New York | 10016 | — |
| Oncology Hematology Care Inc | Cincinnati | Ohio | 45242 | — |
| Willamette Valley Cancer Ctr - 520 Country Club | Eugene | Oregon | 97401-8122 | — |
| Oregon Health Sciences Uni | Portland | Oregon | 97239 | — |
| Sarah Cannon Cancer Center - Tennessee Oncology, Pllc | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Baylor Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78217 | — |
| Texas Transplant Inst. | San Antonio | Texas | 78229 | — |
| Texas Oncology, P.A. - Tyler; Tyler Cancer Center | Tyler | Texas | 75702 | — |
| Fairfax N Virginia Hem/Onc PC | Fairfax | Virginia | 22031 | — |
| Oncology & Hematolgy Associates of SW Va Inc. - Roanoke | Roanoke | Virginia | 24014 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Northwest Cancer Specialists - Vancouver | Vancouver | Washington | 98684 | — |
| Yakima Valley Memorial Hospital/North Star Lodge | Yakima | Washington | 98902 | — |
| Univ of Wisconsin-Madison | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01691898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 21, 2020 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01691898 live on ClinicalTrials.gov.